Literature DB >> 10632574

Geldanamycin induces heat shock protein expression through activation of HSF1 in K562 erythroleukemic cells.

H R Kim1, H S Kang, H D Kim.   

Abstract

HSP90 is one of the most abundant heat shock proteins (HSPs) in eukaryotic cells and is found in complex with several regulatory proteins such as kinases and transcription factors. Geldanamycin (GA), a benzoquinone ansamycin, specifically binds to HSP90 and disrupts the interaction of HSP90 and target proteins. Thus, GA has been used as a specific inhibitor of HSP90. In this study, we examined whether GA could affect protein synthesis and gene expression in the human erythroleukemic cell line K562. Treatment with GA, but not herbimycin A (another benzoquinone ansamycin), highly induced a 70-kDa protein, which was revealed to be HSP70 by immunoblotting and immunoprecipitation with anti-HSP70 antibody. The expression of HSP28 was also enhanced by GA. Furthermore, GA induced the activation of heat shock factor 1 (HSF1), but not HSF2, as determined by electromobility shift and electromobility supershift assay. In addition, similar to heat shock treatment, GA induced the phosphorylation of HSF1. Heat shock element-binding activity and phosphorylation of HSF1 were attenuated 3 h after GA treatment. These results indicate that the functional inactivation of HSP90 by GA potentially stimulates the expression of heat shock proteins through activation of HSF1.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10632574     DOI: 10.1080/713803536

Source DB:  PubMed          Journal:  IUBMB Life        ISSN: 1521-6543            Impact factor:   3.885


  41 in total

1.  Alternative approaches to Hsp90 modulation for the treatment of cancer.

Authors:  Jessica A Hall; Leah K Forsberg; Brian S J Blagg
Journal:  Future Med Chem       Date:  2014-09       Impact factor: 3.808

Review 2.  Heat shock proteins as emerging therapeutic targets.

Authors:  Csaba Sõti; Enikõ Nagy; Zoltán Giricz; László Vígh; Péter Csermely; Péter Ferdinandy
Journal:  Br J Pharmacol       Date:  2005-11       Impact factor: 8.739

3.  Inhibition of heat shock protein 90 alleviates steatosis and macrophage activation in murine alcoholic liver injury.

Authors:  Aditya Ambade; Donna Catalano; Arlene Lim; Andre Kopoyan; Scott A Shaffer; Pranoti Mandrekar
Journal:  J Hepatol       Date:  2014-05-22       Impact factor: 25.083

4.  Systematic identification of the HSP90 candidate regulated proteome.

Authors:  Zhixiang Wu; Amin Moghaddas Gholami; Bernhard Kuster
Journal:  Mol Cell Proteomics       Date:  2012-02-14       Impact factor: 5.911

5.  Heat Shock Protein 90 Modulates Lipid Homeostasis by Regulating the Stability and Function of Sterol Regulatory Element-binding Protein (SREBP) and SREBP Cleavage-activating Protein.

Authors:  Yen-Chou Kuan; Tsutomu Hashidume; Takahiro Shibata; Koji Uchida; Makoto Shimizu; Jun Inoue; Ryuichiro Sato
Journal:  J Biol Chem       Date:  2016-12-21       Impact factor: 5.157

6.  Inhibition of heat shock protein (molecular weight 90 kDa) attenuates proinflammatory cytokines and prevents lipopolysaccharide-induced liver injury in mice.

Authors:  Aditya Ambade; Donna Catalano; Arlene Lim; Pranoti Mandrekar
Journal:  Hepatology       Date:  2012-03-18       Impact factor: 17.425

Review 7.  Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket.

Authors:  Alison Donnelly; Brian S J Blagg
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

8.  Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumors.

Authors:  Joleen Hubbard; Charles Erlichman; David O Toft; Rui Qin; Bridget A Stensgard; Sara Felten; Cynthia Ten Eyck; Gretchen Batzel; S Percy Ivy; Paul Haluska
Journal:  Invest New Drugs       Date:  2010-01-15       Impact factor: 3.850

9.  Cisplatin abrogates the geldanamycin-induced heat shock response.

Authors:  Andrea K McCollum; Kara B Lukasiewicz; Cynthia J Teneyck; Wilma L Lingle; David O Toft; Charles Erlichman
Journal:  Mol Cancer Ther       Date:  2008-10       Impact factor: 6.261

10.  Cucurbitacin D Is a Disruptor of the HSP90 Chaperone Machinery.

Authors:  Jessica A Hall; Sahithi Seedarala; Nichole Rice; Lucas Kopel; Fathi Halaweish; Brian S J Blagg
Journal:  J Nat Prod       Date:  2015-03-10       Impact factor: 4.050

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.